Independent, evidence-based peptide science intelligence. Our editorial team combines expertise in peptide chemistry, molecular pharmacology, and biotech industry analysis.
Eight companies are racing to launch biosimilar semaglutide, but $500M capital requirements and 40+ process patents will limit the field to 3-4 entrants. The first biosimilar is expected in 2028 at a 25-35% discount — not the 80-90% of small-molecule generics.
TIDES 2026: oral GLP-1/GIP dual agonists at 4.8% bioavailability, kilo-scale enzymatic macrocycle cyclization, FDA purity signals, first AI-designed peptide in the clinic, and India's GMP peptide manufacturing debut.
Chinese CDMOs added 1.8 tons of annual SPPS capacity in 3 years, on track for 40% of global peptide API production by 2028. Capital costs are 60% lower than Europe, and FDA inspection records are clean. The risk is not quality — it is geopolitics.
Peptide biotech raised $4.7B in H1 2026 — on pace for another record year. But three deals captured 52% of the total, and the GLP-1 gravity well is starving AMPs, biomaterials, and non-metabolic programs of capital.
Semaglutide vs tirzepatide: the defining rivalry in the $100B obesity market. Tirzepatide delivers 21.1% weight loss vs 15.2% for semaglutide at 72 weeks — but real-world access, not trial data, is increasingly determining prescribing decisions.
A comprehensive guide to peptide drug development in 2026: discovery technologies, synthesis methods, therapeutic classes, delivery systems, regulatory pathways, manufacturing economics, and market dynamics. For researchers, investors, and industry professionals.
Peptide therapeutics for Alzheimer's, Parkinson's, and ALS face the blood-brain barrier — the central unsolved challenge in CNS drug delivery. Three BBB-penetration strategies are in clinical testing, but no peptide has yet shown Phase III efficacy. Rare neurodegenerative diseases may be the breakthrough indication.
Peptide library technologies have evolved from phage display (10⁹ diversity) to RaPID mRNA display (10¹³ diversity, 400+ non-canonical amino acids). But library size is not quality — functional diversity and physiologically relevant selection conditions determine success more than raw numbers.
Semaglutide manufacturing consumes 6.4 tons of peptide API annually across four continents, with $16.5B in capacity expansion underway. The lipidated 31-amino acid chain and 40+ process patents create formidable barriers for biosimilar entrants — only 3-4 competitors are expected by 2032.
The peptide CDMO market reached $4.2B in 2026, with Bachem, PolyPeptide, and CordenPharma controlling 60% of capacity. GLP-1 demand has effectively sold out production-scale reactors through 2028. Developers face a critical build-vs-buy decision with a 50-100 kg/year breakeven point.
Peptide biomaterials — self-assembling hydrogels and nanofibers — are entering clinical use in hemostasis, wound healing, and tissue engineering. With programmable degradation, bioactive signaling, and batch reproducibility, they address regulatory concerns about animal-derived materials like Matrigel.
Cosmetic peptides represent a $3.2B market growing at 12% annually. Signal peptides, neurotransmitter inhibitors, and carrier peptides target distinct skin biology pathways — but the permeability barrier limits efficacy to 1-5% of applied dose. The delivery system matters as much as the peptide.
Matrixyl sends a fake distress signal to fibroblasts using a five-amino-acid collagen fragment called KTTKS. Here is the full molecular mechanism, clinical data, and what formulators get wrong about concentration and delivery.
Clean skincare brand Mad Hippie launches the Wrinkle Relaxing Eye Treatment ($34.99) — five peptide complexes including Syn-Ake, Argireline Amplified and Matrixyl Synthe'6 in a retinol- and Botox-free eye cream.
